Targacept Scientists to Present at the 37th Annual Meeting of the Society for Neuroscience
2007 NOV 12 -- Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), announced plans for its scientists to make poster presentations at the 37th annual meeting of the Society for Neuroscience (SFN). The SFN meeting will be held November 3-7, 2007 at the San Diego Convention Center. Prior to the meeting, a satellite symposium, entitled "Nicotinic Acetylcholine Receptors as Therapeutic Targets: Emerging Frontiers in Basic Research & Clinical Science," will be held October 31-November 2 at the same venue and will highlight the work being performed in the NNR space. Targacept is a leader in this field, with more than 20 years of focused research and investment in NNR science. Patrick M. Lippiello, Ph.D., one of the founders of Targacept, will serve as chairman for a session on attention deficit hyperactivity disorder, depression and epilepsy. Keywords: ADHD, Attention Deficit Hyperactivity Disorder, Biopharmaceuticals, Central Nervous System Disease, Drugs, Epilepsy, Mental Health, Neuroscience, Pharmaceuticals, Therapies, Therapy, Treatment, Targacept Inc. This article was prepared by Pain & Central Nervous System Week editors from staff and other reports. Copyright 2007, Pain & Central Nervous System Week via NewsRx.com.
|
